POSIMIR Market Size, Forecast, and Market Insight - 2032

"POSIMIR Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about POSIMIR for Postoperative pain in the seven major markets. A detailed picture of the POSIMIR for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the POSIMIR for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the POSIMIR market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

POSIMIR (SABER-bupivacaine, also previously known as POSIDUR) for infiltration use is a novel and proprietary product that combines the strength of 660 mg of bupivacaine base with the innovative SABER platform technology, enabling continuous sustained delivery of a non-opioid local analgesic over 3 days in adults. It contains a local amide anesthetic and is indicated in adults for administration into the subacromial space under direct arthroscopic visualization to produce postsurgical analgesia for up to 72 h following arthroscopic subacromial decompression.

The company decided to change the drug's name because the FDA was concerned with POSIDUR. In 2014, the US regulator told the company that investigators did not provide sufficient data to prove that it could be safely administered and would need additional safety studies. This came 2 years after the program failed an efficacy test in a late-stage study.

Mechanism of action

Bupivacaine blocks the generation and the conduction of nerve impulses by increasing the threshold for electrical excitation in the nerve, slowing the nerve impulses propagation, and reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of a loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the POSIMIR description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on POSIMIR regulatory milestones and other development activities have been provided in this report.
• The report also highlights the POSIMIR research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around POSIMIR.
• The report contains forecasted sales of POSIMIR for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for POSIMIR in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

POSIMIR Analytical Perspective by DelveInsight

• In-depth POSIMIR Market Assessment

This report provides a detailed market assessment of POSIMIR for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• POSIMIR Clinical Assessment

The report provides the clinical trials information of POSIMIR for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence POSIMIR dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to POSIMIR and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of POSIMIR in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of POSIMIR from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the POSIMIR in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of POSIMIR?
• What is the clinical trial status of the study related to POSIMIR in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the POSIMIR development?
• What are the key designations that have been granted to POSIMIR for Postoperative pain?
• What is the forecasted market scenario of POSIMIR for Postoperative pain?
• What are the forecasted sales of POSIMIR in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to POSIMIR for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?